Drug Combination Details
| General Information of the Combination (ID: C70316) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GLI2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IGF2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PTCH1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
| NIH 3T3 | CVCL_0594 | Healthy | Mus musculus | |||
| Experimental
Result(s) |
Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Ovarian carcinoma cells on concurrent or 5-FU followed by BA treatment show increased Sub-G1 cell population, increased rate of cell apoptosis and morphological changes in mitochondrial membrane. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Int J Clin Exp Pathol. 2015 Jan 1;8(1):252-9. | |||
